Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Patents 152show all

  • 102
    C07K - Peptides
  • 95
    A61K - Preparations for medical, dental, or toilet purposes
  • 70
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 28
    C12N - Microorganisms or enzymes
  • 11
    Y02A - Technologies for adaptation to climate change

Clinical Trials 4show all

2Phase 11N/A1Phase 2

SEC Filings show all


6
D

Contact Information

Seattle Life Sciences Building 1124 Columbia Street, Suite 300
Seattle, WA 98104
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$64,172,60311-502015-05-07Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2010-03-17$1,500,000Series UnknownARCH Venture Partners, Amgen Ventures, HealthCare Ventures, Alexandria Real Estate Equities, Canaan Partners, MPM Capital
2015-05-07$3,080,000Series Unknown
2004-12-09$408,000Series A
2011-11-08$11,584,603Series Unknown
2013-03-25$8,000,000Series BARCH Venture Partners, Versant Ventures, Canaan Partners, Alexandria Real Estate Equities, MPM Capital, HealthCare Ventures, Amgen Ventures, Zenyaku Kogyo
2006-03-03$4,600,000Series AInstitute for Systems Biology, ARCH Venture Partners, Amgen Ventures
2013-03-25$6,000,000Debt FinancingMidCap Financial, Silicon Valley Bank
2007-03-19$29,000,000Series BCanaan Partners, HealthCare Ventures, ARCH Venture PartnersAmgen Ventures, Alexandria Real Estate Equities, MPM Capital

SEC Form D Funding Events

DateOfferedSoldType
2013-07-29$6,396,000$6,000,000Debt, Option to Acquire, Security to be Acquired
2013-03-26$8,000,001$4,000,000Equity, Security to be Acquired
2011-11-23$11,584,603$11,584,603Equity
2010-03-17$1,500,000$1,500,000Equity, Other
2007-03-23Unknown Unknown Other (Paper Filing)

Key Executives

  • David Fanning
    Executive Officer, Director
  • Russ Hawkinson
    Executive Officer
  • Steven Gillis
    Executive Officer, Director
  • Wende Hutton
    Director
  • Christopher Mirabelli
    Director
  • William Greene
    Director
  • Clifford Stocks
    Executive Officer, Director
  • Kristine Swiderek
    Executive Officer
  • Witold Cieplak
    Executive Officer
  • Wendye Robbins
    Director
  • Eleanor Ramos
    Executive Officer